Lenacapavir-GS-6207-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemELenacapavirCat.No.:HY-111964CASNo.:2189684-44-2Synonyms:GS-6207分?式:C??H??ClF??N?O?S?分?量:968.28作?靶點(diǎn):HIV作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:200mg/mL(206.55mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.0328mL5.1638mL10.3276mL5mM0.2066mL1.0328mL2.0655mL10mM0.1033mL0.5164mL1.0328mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoil1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥6.25mg/mL(6.45mM);Clearsolution2.請(qǐng)依序添加每種溶劑：5%DMSO>>40%PEG300>>5%Tween-80>>50%salineSolubility:2.5mg/mL(2.58mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性L(fǎng)enacapavir(GS-6207)?種HIV-1?抑制劑。在MT-4細(xì)胞中，Lenacapavir具有抗HIV活性，EC50為100pM，在外周?單個(gè)核細(xì)胞中，對(duì)23種來(lái)?不同亞型的HIV-1臨床分離株的平均EC50為50pM(20-160pM)[1]。IC50&TargetEC50:100pM(anti-HIV;inMT-4cells)[1]體外研究Lenacapavir(GS-6207)isapotentcapsid-targetinginhibitorofHIVreplication.Lenacapavirshowssub-nanomolarpotencyintargetcells(EC50=23pM),inafull-cycleassay(EC50=25pM)andinproducercells(EC50=439pM).LenacapavirinterfereswithboththeearlyandlatestagesofHIV-1replicationbutexhibitsgreaterpotencyagainsttheearlystage[2].戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Viruses.2022May31;14(6):1202.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].SinghK,etal.GS-CACompounds:First-In-ClassHIV-1CapsidInhibitorsCoveringMultipleGrounds.FrontMicrobiol.2019Jun20;10:1227.[2].JohnOLink,etal.ClinicaltargetingofHIVcapsidproteinwithalong-actingsmallmolecule.Nature.2020Jul1.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Te